Perifosine News and Research

RSS
Perifosine is a substance that is being studied in the treatment of cancer. Perifosine is an orally active alkyl-phosphocholine compound with potential antineoplastic activity. Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis. Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine.
Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented

Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

FDA grants Fast Track designation for Keryx Biopharmaceuticals' KRX-0401

FDA grants Fast Track designation for Keryx Biopharmaceuticals' KRX-0401

FDA grants Fast Track designation for AEterna Zentaris' perifosine

FDA grants Fast Track designation for AEterna Zentaris' perifosine

Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting

Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

Keryx Biopharmaceuticals commences Phase 2 clinical study evaluating KRX-0401 for Chronic Lymphocytic Leukemia

Keryx Biopharmaceuticals commences Phase 2 clinical study evaluating KRX-0401 for Chronic Lymphocytic Leukemia

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Gene that stops or suppress cancer plays a role in cancer stem cells

Gene that stops or suppress cancer plays a role in cancer stem cells

Researchers examine immune cells where HIV can lie dormant, possible treatments

Researchers examine immune cells where HIV can lie dormant, possible treatments